Recursion Pharmaceuticals, INC Form 4 insider transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions, as part of a pre-arranged trading plan.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock at an average price of $12.0577 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.